Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin
Katherine A Maclean, Jeannie‐marie Leoutsakos, Matthew W. Johnson, Roland R. Griffiths
Journal for the Scientific Study of Religion December 1, 2012 DOI: 10.1111/j.1468-5906.2012.01685.x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Exploratory factor analysis with confirmatory factor analysis in a replication sample Peer reviewed |
|---|---|
| Sample size | 1,602 |
| Population | Adults who had ingested psilocybin and reported a mystical or profound experience |
| Intervention | Psilocybin |
| Topics | Mysticism Psilocybin Mystical experience |
| Keywords | Hallucinogen Exploratory factor analysis Psychometrics |
| Citations | 412 |
| Key points | The 30-item Mystical Experience Questionnaire has a valid four-factor structure capturing unity/noetic quality/sacredness, positive mood, transcendence of time/space, and ineffability, and distinguishes those who had a mystical experience from those who did not. |
Abstract
A large body of historical evidence describes the use of hallucinogenic compounds, such as psilocybin mushrooms, for religious purposes. But few scientific studies have attempted to measure or characterize hallucinogen‐occasioned spiritual experiences. The present study examined the factor structure of the Mystical Experience Questionnaire (MEQ), a self‐report measure that has been used to assess the effects of hallucinogens in laboratory studies. Participants (N = 1,602) completed the 43‐item MEQ in reference to a mystical or profound experience they had had after ingesting psilocybin. Exploratory factor analysis of the MEQ retained 30 items and revealed a four‐factor structure covering the dimensions of classic mystical experience: unity, noetic quality, sacredness (F1); positive mood (F2); transcendence of time/space (F3); and ineffability (F4). MEQ factor scores showed good internal reliability and correlated with the Hood Mysticism Scale, indicating convergent validity. Participants who endorsed having had a mystical experience on psilocybin, compared to those who did not, had significantly higher factor scores, indicating construct validity. The four‐factor structure was confirmed in a second sample (N = 440) and demonstrated superior fit compared to alternative models. The results provide initial evidence of the validity, reliability, and factor structure of a 30‐item scale for measuring single, hallucinogen‐occasioned mystical experiences, which may be a useful tool in the scientific study of mysticism.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
The 30-item Mystical Experience Questionnaire showed a valid four-factor structure (unity/noetic quality/sacredness, positive mood, transcendence of time/space, ineffability) and distinguished those who had a mystical experience from those who did not.
Synthesized
-
State of the evidence: Mysticism Supports
The 30-item Mystical Experience Questionnaire showed a four-factor structure (unity/noetic quality/sacredness, positive mood, transcendence of time/space, ineffability) with good reliability, convergent validity with the Hood Mysticism Scale, and construct validity distinguishing those who had a mystical experience from those who did not.
Synthesized
Citations in the library
Cited by 327
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
and 322 more in the library
Cites 18
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later Journal of Psychopharmacology May 30, 2008
- Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) PLoS One August 31, 2010
and 13 more in the library